In the 2-year AFFIRM pivotal trial:

83% of patients taking TYSABRI had no sustained physical disability progression for 12 weeks vs 71% with placebo (primary endpoint: percentage with sustained increase in disability was 17% vs 29%; p<0.001)1,2

View the complete AFFIRM study description.

FIND COVERAGE AND REIMBURSEMENT SUPPORT

Biogen offers assistance throughout the coverage and reimbursement process

  • For the majority of insured patients, TYSABRI requires only a single step or no step at all
  • For patients who have not met the step requirement, payers typically have a pathway for earlier use through the medical exceptions process
    • Research with multiple health plans indicates that medical exceptions for TYSABRI are typically approved, provided that an appropriate clinical justification is communicated

ACCESS AND REIMBURSEMENT GUIDE

Biogen is committed to providing access and reimbursement support to physician offices and infusion sites that administer TYSABRI

Download a guide designed to provide information that can help practice administrators and other key practice staff understand the administrative needs and various aspects of the reimbursement process: prescribing and ordering TYSABRI, billing and claims filing, patient support, healthcare reform, FAQs, and a Managed Care Glossary.

BILLING AND CLAIMS FILING

Get information for both physician offices and hospital outpatient/infusion sites, such as key billing codes, payer coverage, payment for drugs/services, and claims denials/appeals

Download resources and sample forms that your office, hospital, and/or infusion site might find useful.

Only prescribers, pharmacies, and infusion sites enrolled in the TOUCH® Prescribing Program (REMS program) are able to prescribe, distribute, or infuse TYSABRI.

AFFIRM=NAtalizumab Safety and EFFIcacy in Relapsing-Remitting MS.